Natco Pharma gets USFDA nod for cancer generic drug
Natco’s Erdafitinib is approved for adult patients with advanced unresectable or metastatic urothelial carcinoma and FGFR3 genetic alterations who have progressed after at least one prior therapy
Natco’s Erdafitinib is approved for adult patients with advanced unresectable or metastatic urothelial carcinoma and FGFR3 genetic alterations who have progressed after at least one prior therapy
What's Your Reaction?
Economist Admin
Admin managing news updates, RSS feed curation, and PR content publishing. Focused on timely, accurate, and impactful information delivery.
